Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance

Christina Yap,Olga Solovyeva,Johann de Bono,Jan Rekowski,Dhrusti Patel,Thomas Jaki,Adrian Mander,Thomas R Jeffry Evans,Richard Peck,Kathryn S Hayward,Sally Hopewell,Moreno Ursino,Khadija Rerhou Rantell,Melanie Calvert,Shing Lee,Andrew Kightley,Deborah Ashby,An-Wen Chan,Elizabeth Garrett-Mayer,John D Isaacs,Robert Golub,Olga Kholmanskikh,Dawn Richards,Oliver Boix,James Matcham,Lesley Seymour,S Percy Ivy,Lynley V Marshall,Antoine Hommais,Rong Liu,Yoshiya Tanaka,Jordan Berlin,Aude Espinasse,Munyaradzi Dimairo,Christopher J Weir
DOI: https://doi.org/10.1136/bmj-2023-076387
2023-10-20
BMJ
Abstract:The CONSORT (CONsolidated Standards Of Reporting Trials) 2010 statement is the standard guideline for reporting completed randomised trials. The CONSORT Dose-finding Extension (DEFINE) extends the guidance (with 21 new items and 19 modified items) to early phase dose-finding trials with interim dose escalation or de-escalation strategies. Such trials generally focus on safety, tolerability, activity, and recommending dosing and scheduling regimens for further clinical development. These trials are often inadequately reported, hampering their informativeness and making evidence informed decisions difficult. The CONSORT-DEFINE guidance aims to develop an international, consensus driven guideline for reporting early phase dose-finding trials to promote transparency, completeness, reproducibility, and facilitate the interpretation of the results. The CONSORT-DEFINE guidance provides recommendations for essential items that should be reported in early phase dose-finding trials to promote greater clarity, reproducibility, informativeness, and usefulness of results.
What problem does this paper attempt to address?